Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : GelTex Pharmaceuticals (GELX) -- Ignore unavailable to you. Want to Upgrade?

To: EACarl who wrote (91)	10/6/1998 3:34:00 PM
From: Robert L. Ray	Read Replies (2) \| Respond to of 127

Glad to see the H & Q upgrade. It would be even nicer if GELX could hold on to the gains a little better:) Oh well, in due time I suppose. Another Yahoo link has appeared with a few more details. I kinda like to do copy/pastes on the Yahoo links to the thread because they expire fairly quickly. biz.yahoo.com Tuesday October 6, 1:12 pm Eastern Time RESEARCH ALERT - Geltex raised LOS ANGELES, Oct 6 (Reuters) - Hambrecht & Quist raised its rating on stock of GelTex Pharmaceuticals Inc to strong buy from buy ahead of milestones for two late stage drugs. -- said expects U.S. Food and Drug Administration approval of the company's first product, RenaGel, by Nov. 2. said ''is possible'' drug could be approved by a meeting of the American Society of Nephrology being held Oct. 25 - 28. -- said Phase III data on a second lead drug, CholestaGel, is expected in the first quarter of next year. -- noted stock is trading only about 3 points over its 52-week low of 15 and well off its 52-week high of 32. -- Stock was up 1-1/8 at 18-1/8 by mid-afternoon.